DESENSITISATION PROTOCOL TO COVID-19 VACCINES: COLLABORATION BETWEEN HOSPITAL PHARMACIST AND ALLERGIST

BACKGROUND AND IMPORTANCE
Covid-19 vaccines were administered worldwide and allergic reactions may arise, especially in subjects with a prior history of allergy. As indicated in AAIITO Guidelines (Association of Italian Allergists Immunologist) and SIAAIAC (Italian Society of Allergy, Asthma and Clinical Immunology), in case of immediate allergic reaction, but not anaphylactic one, after the first dose of Covid-19 mRNA vaccine, skin test were performed to value PEG (polyethylene glycol) and polysorbate allergies; if negative, the second dose could be administered with the desensitization method proposed by the Position Paper EAACI (European Academy of Allergy and Clinical Immunology). It suggested the administration in intervals of 15-30 minutes of 0.05ml of the 1:10 dilution of the dose vaccine, then 0.05ml, 0.10ml, 0.15ml of the dose that would be normally administered.

AIM AND OBJECTIVES
The aim of this work were to show the adaptation of a desensitization protocol already in use for Covid-19 mRNA vaccines to the viral vector-based one, to quantify preparations, to evaluate the patients treated and outcomes. The period analyzed were February 2021-October 2021.

MATERIALS AND METHODS
The hospital pharmacist with the allergist created a protocol to prepare the desensitization doses, that were set up in a sterile hood. The correct dilutions were calculated and an informatic file filled in with the information about patients (anamnesis, gender, age, outcome).

RESULTS
The treated patients were 15, for each one were prepared 4 syringes; 60 total doses. All patients had previous history of polyallergy, female and with average age of 54 years. Finally, 14 patients completed the doses without adverse reactions, only one patients developed an asthma attack.

CONCLUSION AND RELEVANCE
This work shows how the close collaboration between allergist and hospital pharmacist led to the creation of a desensitization protocol that provides an important therapeutic option, with a good outcome, for allergic patients in vaccination campaign for Covid-19.

REFERENCES
"Guidelines for the management by allergists of patients at risk of allergic reaction to vaccines for Covid-19".AAIITO and SIAAIAC guidelines.

CONTACT DATA: veronica15x@gmail.com